Australia's medicines regulator has placed a quiet but consequential warning into the expanding story of GLP-1 weight-loss drugs — a reminder that even celebrated medicines carry shadows. The Therapeutic Goods Administration, having identified 36 cases of a rare optic nerve condition causing permanent vision loss, has updated safety information for Ozempic, Wegovy, and Mounjaro. The condition, NAION, leaves no room for remedy once it takes hold, making awareness and early response the only available shield. In an era when these drugs have reshaped how millions approach weight and metabolic hea
TGA warns of rare eye disorder risk with GLP-1 obesity drugs; Christian Brothers agree to full abuse compensation
36 reported cases of permanent vision loss associated with GLP-1 medications, with potential for irreversible blindness in affected patients.